SMT launches Hydra TAVR system in Mexico

IMT News Desk
IMT News Desk
· 2 min read

Hydra is the first TAVR device to incorporate frame markers, ensuring precise implantation and ease of deployment

Mumbai-based Sahajanand Medical Technologies (SMT) has launched Hydra Transcatheter Aortic Valve Replacement (TAVR) system in Mexico.

The Hydra TAVR system features advanced innovations, including:

  • Frame Markers: Hydra is the first TAVR device to incorporate frame markers, ensuring precise implantation and ease of deployment.
  • Supra-Annular Design: This enhances hemodynamic performance, delivering a larger effective valve area for improved patient recovery and quality of life.
  • Bovine Pericardium: The valve is crafted with high-quality bovine pericardium for durability and reliability.
  • Reduced Trauma Design: Hydra’s flexible frame reduces trauma to the aortic arch, while its sealing skirt minimises paravalvular leaks for improved safety.
  • Future-Proof Access: Large open cells in the stent frame ensure easy coronary access for future interventions.

“With the approval of Hydra in Mexico, we are empowering physicians with an advanced TAVR system that combines precision, safety, and superior hemodynamics,” said Joao Rodrigues, Head of Latin America at SMT. “This milestone underscores our commitment to saving lives and transforming cardiac care in Latin America.”

Hydra’s approval by COFEPRIS, Mexico’s Federal Commission for Protection Against Sanitary Risks, is a testament to SMT’s dedication to meeting stringent regulatory requirements. COFEPRIS is recognised for its rigorous evaluation standards, ensuring the safety and efficacy of healthcare technologies introduced in the Mexican market.

“It is expected that COFEPRIS requires comprehensive technical and clinical data for product registration, which after several rounds of reviews SMT successfully addressed and provided the agency with all required technical and clinical studies We are incredibly proud of this achievement,” added Ammad Shorbaji, Vice President of Regulatory Affairs, SMT.

Read Next

Agenus announces closing of $141 M strategic collaboration with Zydus Lifesciences
Global News
January 20, 2026

Agenus announces closing of $141 M strategic collaboration with Zydus Lifesciences

To advance BOT+BAL and strengthen US manufacturing readiness Agenus, a leader in immuno-oncology innovation, announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The agreement is designed to accelerate global development and potential commercialisation of Agenus’ botensilimab and balstilimab (BOT+BAL) immunotherapy combination programme. The collaboration provides Agenus with strategic capital and […]
Article by: IMT News Desk
Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia
Global News
January 16, 2026

Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia

Approval marks Venus Remedies’ first anti-infective marketing authorisation in Indonesia and enables the country’s first generic entry for this critical antibiotic combination Venus Remedies has secured the marketing authorisation from the Indonesian regulatory authority for its combination antibiotic, Ceftazidime + Avibactam. This approval represents Venus Remedies’ first marketing authorization in the anti-infective segment in Indonesia […]
Article by: IMT News Desk
Wegovy pill approved in the US for weight management
Global News
December 26, 2025

Wegovy pill approved in the US for weight management

Novo Nordisk expects to launch the Wegovy pill in the US in early January 2026 Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse […]
Article by: IMT News Desk
Samsung Biologics America in agreement to acquire 100 per cent of Human Genome Sciences from GSK
Global News
December 24, 2025

Samsung Biologics America in agreement to acquire 100 per cent of Human Genome Sciences from GSK

Under the terms of the agreement, with closing anticipated toward the end of Q1 of 2026, Samsung Biologics will acquire the Rockville assets for $280 million Samsung Biologics, a leading contract development and manufacturing organization (CDMO), announced that its wholly owned US subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100 […]
Article by: IMT News Desk